Evidence map›Paper›PMID 20103726›Full record

ReviewCancer prevention research (Philadelphia, Pa.)2010

Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung.

Eva Szabo

Open access · bronzeAbstract readCommentReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Lung cancer chemoprevention with celecoxib in former smokers.Cancer prevention research (Philadelphia, Pa.) · 2011
    Trial
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Eva SzaboLung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland 20892, USA. szaboe@mail.nih.gov
National Cancer Institute · US

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

This perspective on Kim et al. (beginning on p. 148 in this issue of the journal) examines the value of the Ki-67 proliferation index as a surrogate end point in early-phase clinical lung cancer prevention trials. The clinical trial of Kim et al. shows an effect of the cyclooxygenase-2-selective inhibitor celecoxib at a high dose on Ki-67 expression in the normal bronchial epithelia of current and former smokers. The critical issue of how these data can be used to further drug development is discussed.

Indexed as

Antineoplastic AgentsBiomarkers, TumorCelecoxibClinical Trials as TopicHumansKi-67 AntigenLung NeoplasmsPyrazolesRespiratory MucosaSulfonamidesAntineoplastic AgentsBiomarkers, TumorCelecoxibKi-67 AntigenPyrazolesSulfonamides

Identifiers

PMID20103726
PMCPMC2818869
OpenAlexW2118285973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.